Cargando…
Trends in Women’s Leadership of Oncology Clinical Trials
It has been widely reported that women are underrepresented in leadership positions within academic medicine. This study aimed to assess trends in women representation as principal investigators (PIs) in oncology clinical trials and to characterize trends in women’s leadership in such trials conduct...
Autores principales: | Waldhorn, Ithai, Dekel, Ayelet, Morozov, Anna, Alon, Elisa Sardas, Stave, Danielle, Tsrooya, Noam Ben, Schlosser, Shir, Markel, Gal, Bomze, David, Meirson, Tomer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215172/ https://www.ncbi.nlm.nih.gov/pubmed/35756628 http://dx.doi.org/10.3389/fonc.2022.885275 |
Ejemplares similares
-
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020) -
Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022) -
Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer
por: Meirson, Tomer, et al.
Publicado: (2023) -
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020) -
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)